The director of the Epilepsy Center and vice chair of the Neurological Institute for Strategy and Development at Cleveland Clinic relayed his excitement for a new advanced imaging tool that could change how epilepsy specialists diagnose and treat the disease.
The phase 2/3 trials will end after a futility analysis suggested that the drug is not likely to show a clinical benefit.
The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic offered insight into the challenges that have plagued physicians in identifying biomarkers for Lewy body dementia.
The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation shared his unique perspective on spinal cord injury and the work he and colleagues are doing to alleviate its challenges.
Imad Najm, MD, details how advanced telemedicine technology has created a paradigm shift in the way physicians see and treat patients at Cleveland Clinic and around the world.
UCB’s intranasal midazolam spray (Nayzilam), an FDA-approved therapy for seizure clusters, has shown success and rapid efficacy in status epilepticus, with treatment effect occurring approximately 4 to 5 minutes post-administration.
Data show patients with high frequency episodic migraine are comparable to those with chronic migraine in regard to chronicity and disability.
The director of the Epilepsy Center at Cleveland Clinic spoke about the challenges faced when identifying focal cortical dysplasia.
A new analysis from the phase 3 HALO development program showed that Teva’s CGRP inhibitor fremanezumab (Ajovy) separated from placebo by Day 2 posttreatment, suggesting not only rapid clinical improvement, but the potential to positively impact treatment adherence.
The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the available options for Parkinson dementia and how they compare in Alzheimer, as well as the ongoing development in Alzheimer.
The Green Valley agent, which is derived from seaweed, showed significant improvements in ADAS-Cog scores over placebo and is anticipated to make its debut on the market in China in late 2019.
Study results suggest that as many as 20% of patients may be nonadherent to medication regimens, with youth having the strongest association with intentional nonadherence.
The neurologist at Thomas Jefferson University Hospitals discussed the pros and cons of supplemental drugs used to reduce off time in patients with Parkinson disease.
The 2019 update to the 2018 guidelines clarifies prior recommendations and takes into consideration new clinical trial data to offer a comprehensive guide for treatment, from symptom onset through 2 weeks after acute ischemic stroke.
The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the ground that has been made in treating dementia, and how nuance in diagnosis can provide a possible leg up for physicians.
The neurologist at Cleveland Clinic outlines the need to better understand the biology of progressive MS in order to make substantial headway in its treatment.
Neurology News Network for the week ending October 28, 2019.
The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.
In Part 2 of this interview, Amaal Starling, MD, assistant professor of neurology at Mayo Clinic Scottsdale, discussed what still needs to be done in the migraine space in light of recent advancements and how disease-specific therapies are just the beginning for the field.
The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the diagnostic differences between Lewy body dementia, Alzheimer disease, and other dementias, as well as the importance of proper identification.
In an interview with NeurologyLive, Andrew S. Feigin, MD, details ongoing trials that aim to treat Huntington disease, including the notable SIGNAL trial.
The neurologist at Cleveland Clinic discusses the clinical considerations included in the decision to stop treatment of MS in patients with progressive disease.
In Part 1 of this interview, Amaal Starling, MD, assistant professor of neurology at Mayo Clinic Scottsdale, shared her experiences with a number of new migraine drugs and devices and the impact that more options will have on clinical practice.
Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.
The breakthrough study is a concrete example of the opportunities that precision medicine present in the pursuit to prevent the onset of or worsening of diseases like Alzheimer dementia.
Bogged down by a decades-long chase for a common pathology, investigators exploring alternative and complimentary theories are pushing to extend their time in the spotlight.
Study results suggest that adherence to individually tailored interventions, including behavioral, dietary, pharmacologic, educational, and other recommendations can have a positive impact on cognition and reduce risk in patients across the clinical spectrum who have a family history of Alzheimer disease.
The staff neurologist at Cleveland Clinic addressed several questions regarding choosing an optimal therapy for patients with MS.
The drug, which is currently approved for single-dose intravenous administration in patients with SMA type 1, is currently being investigated as intrathecal therapy in SMA type 2.
The FDA has granted the go-ahead to Biogen and Alkermes’ diroximel fumarate, which will be marketed as Vumerity, for the treatment of relapsing-remitting and secondary progressive MS, as well as clinically isolated syndrome.
